# Developmental Research Program

> **NIH NIH P50** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2020 · $80,510

## Abstract

PROJECT SUMMARY
The overall goal of the NYU Melanoma SPORE Developmental Research Program (DRP) is to support pilot
projects that take maximum advantage of new research opportunities in melanoma and aid in recruiting
established cancer investigators at the level of Assistant Professor or higher to the translational study of
melanoma. The DRP focuses on and will select innovative and promising translational research projects in
melanoma, and will monitor their progress to ensure that goals are met. The Director of the DRP is Dr. Iannis
Aifantis, the Chair of the NYU Department of Pathology and an internationally regarded investigator who brings
an accomplished track record of mentorship and emerging translational melanoma research success. He will
work together with an internal evaluation panel and the SPORE PD/PIs to identify and support selected pilot
studies with exceptional translational potential. The NYU Melanoma SPORE DRP will support projects for up
to 2 years, enabling awardees to adequately explore the potential of novel topics in translational melanoma
research. Focusing on innovation, the DRP will support the development of “high-risk, high-reward”
investigations in melanoma and encourage proposals for novel approaches to screening, diagnosis, prognosis,
prediction, and treatment of melanoma. The DRP will monitor the progress of all projects and awardees chosen
for funding to ensure that goals are met and that DRP projects may be strongly positioned to replace any
SPORE project either not meeting its translational research goals or completed prior to the close of the award
period.
The DRP is highly integrated thematically and programmatically with the larger NYU Melanoma SPORE and
recognizes that a key component to the growth of the SPORE is the continued support and development of
novel investigations in melanoma, specifically in the area of improved personalized management of melanoma
patients. Both NYU Langone Health (NYULH) and the NYU Perlmutter Cancer Center (PCC) have consistently
used various pilot funding mechanisms to support promising novel approaches to melanoma prognosis, clinical
management, and treatment.

## Key facts

- **NIH application ID:** 9980836
- **Project number:** 5P50CA225450-02
- **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- **Principal Investigator:** Iannis Aifantis
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $80,510
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9980836

## Citation

> US National Institutes of Health, RePORTER application 9980836, Developmental Research Program (5P50CA225450-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9980836. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*